Barriers Identification as Intervention to Engage Breast Cancer Survivors in Physical Activity

This study was designed to demonstrate the advantage of adding cancer barriers to components of decision-making in the transtheoretical model (TTM). In study 1, questionnaires were completed by 139 breast cancer survivors including decisional balance, cancer-related barriers and stages of readiness. In study 2, efficiency of directly tackling cancer-related barriers through motivational-style conversation was tested in a quasi-experimental design. From study 1, all decision-making variables were related to stages of readiness, but cancer-related barriers were the sole predictors of engagement in physical activity. Out of the three groups of study 2, only the group with motivational-style conversation displayed a significant progress for engagement in physical activity. Demonstrating that cancer-related barriers predict stage of change above the effects of the two components of decisional balance provides a validation of positions that put cancer-related barriers as uniquely related to stages of change, and suggests that adding them in decision making variables in TTM’s model can provide a genuinely new contribution to the understanding of physical activity adherence. Regarding implication for cancer survivors, these results suggest that in order to stimulate progress in early stages of change, a greater emphasis may be needed on reducing cancer-related barriers

Prévalence de Toxoplasma gondii chez les animaux péri-domestiques et sauvages en région Provence-Alpes-Côte d'Azur

International audienc

Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1

International audienceTargeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by restoring antitumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Neuropilin-1 (NRP1) is a transmembrane glycoprotein required for nervous system and angiogenesis embryonic development, also expressed in immune cells. We hypothesized that NRP1 could be an immune checkpoint co-receptor modulating CD8+ T cells activity in the context of the antitumor immune response. Here, we show that NRP1 is recruited in the cytolytic synapse of PD1+CD8+ T cells, cooperates and enhances PD-1 activity. In mice, CD8+ T cells specific deletion of Nrp1 improves anti-PD1 antibody antitumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8+ T cells predicts poor outcome of patients treated with anti-PD1. NRP1 is a promising target to overcome resistance to anti-PD1 therapies